Oragenics’ Concussion Treatment Drug Demonstrates Safety Profile Without Heart Risks
Thursday, 8 August 2024, 13:01
Study Overview
Oragenics conducted a study on its concussion drug, revealing no significant heart risks associated with its use.
Key Findings
- The drug demonstrated a favorable safety profile.
- There were no adverse cardiovascular effects noted during the study.
Conclusion
This study not only supports the continued development of the concussion treatment but also reassures stakeholders of its safety, making it a promising option for future applications.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.